Megamet VG 0.2 – Glimepiride 2mg + Voglibose 0.2mg + Metformin SR 500mg Tablets (10’s) | Triple Diabetes Therapy

Description

Megamet VG 0.2 Tablets (10’s) | Glimepiride 2mg + Voglibose 0.2mg + Metformin SR 500mg | Triple Therapy for Type 2 Diabetes Management

Category: Anti-diabetic Combination Therapy
Pack Size: 10 Sustained-Release Tablets (Blister Pack)

Composition (Per Tablet):

• Glimepiride 2mg (Sulfonylurea – Insulin Secretagogue)

• Voglibose 0.2mg (Alpha-Glucosidase Inhibitor – Reduces Postprandial Glucose)

• Metformin SR 500mg (Sustained-Release Biguanide – Insulin Sensitizer)

Key Benefits:
✔️ Triple-Mechanism Action: Controls both fasting and postprandial glucose through complementary pathways
✔️ Sustained-Release Metformin: Reduces GI side effects and allows once-daily dosing
✔️ Targeted Postprandial Control: Voglibose specifically addresses carbohydrate absorption
✔️ Reduced Hypoglycemia Risk: Balanced approach to glucose control

Therapeutic Uses:
• Type 2 diabetes mellitus with prominent postprandial hyperglycemia
• Patients inadequately controlled on dual therapy
• Those experiencing GI intolerance with immediate-release metformin

Dosage (Adults):

• 1 tablet once daily with the first main meal

• Do not crush or chew – swallow whole

• Maximum: 2 tablets daily (under medical supervision)

Safety Profile:
🚫 Contraindications:

• Type 1 diabetes or diabetic ketoacidosis

• Severe renal/hepatic impairment

• Inflammatory bowel disease or intestinal obstruction

• Hypersensitivity to any component

⚠️ Monitor For:
• Hypoglycemia (especially when combined with other antidiabetics)
• GI disturbances (flatulence, diarrhea – usually transient)
• Liver function abnormalities

Drug Interactions:
▲ Significant Interactions:

• Digestive enzymes (reduced voglibose efficacy)

• Beta-blockers (may mask hypoglycemia symptoms)

• Alcohol (increased hypoglycemia risk)

Storage:

• Below 30°C

• Protect from moisture

• Keep in original packaging